Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia.
CD38 monoclonal antibody
daratumumab
hematopoietic stem cell transplantation
non malignant
pediatrics
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
09
2022
accepted:
11
11
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric blood disorders has been in post-transplant autoimmune cytopenias. Here we describe three patients in whom daratumumab was used outside of post-transplant autoimmune cytopenias, highlighting further potential uses of this medication.
Identifiants
pubmed: 36524117
doi: 10.3389/fimmu.2022.1055473
pmc: PMC9744936
doi:
Substances chimiques
daratumumab
4Z63YK6E0E
Antibodies, Monoclonal
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1055473Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Pereda, Hosahalli Vasanna, Desai, Deng, Owusu-Ansah, Dallas, Pateva and Dalal.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transfusion. 2021 Jul;61(7):2054-2063
pubmed: 33960433
Br J Haematol. 2019 Oct;187(2):e48-e51
pubmed: 31441030
Transfusion. 2021 Dec;61(12):3468-3472
pubmed: 34617617
Pediatr Nephrol. 2021 May;36(5):1175-1182
pubmed: 33118048
J Blood Med. 2019 Aug 08;10:265-278
pubmed: 31496855
Pediatr Blood Cancer. 2021 Nov;68(11):e29290
pubmed: 34390168
J Hematol Oncol. 2016 Jun 30;9(1):51
pubmed: 27363983
PLoS One. 2013 Aug 19;8(8):e72141
pubmed: 23977232
Blood Transfus. 2020 Jul;18(4):290-294
pubmed: 32530397
Bone Marrow Transplant. 2015 Jun;50(6):751-8
pubmed: 25706884
Blood. 2011 Dec 15;118(25):6691-7
pubmed: 21940825
Blood. 2010 Oct 14;116(15):2839-46
pubmed: 20628152
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):689-695
pubmed: 34889373
Blood Adv. 2018 Oct 9;2(19):2550-2553
pubmed: 30291113
Pediatr Blood Cancer. 2020 Jan;67(1):e28010
pubmed: 31544339
Mol Cell Pediatr. 2021 Apr 29;8(1):5
pubmed: 33914175
Kidney Int. 2020 May;97(5):885-893
pubmed: 32229095
Biol Blood Marrow Transplant. 2011 Nov;17(11):1704-8
pubmed: 21601639
Front Oncol. 2021 Feb 17;10:624661
pubmed: 33680948
Transfusion. 2019 Dec;59(12):3801-3802
pubmed: 31802512
Haematologica. 2021 Dec 01;106(12):3198-3201
pubmed: 34348453
J Am Soc Nephrol. 2021 May 3;32(5):1163-1173
pubmed: 33685975
Pediatr Blood Cancer. 2020 Sep;67(9):e28591
pubmed: 32658382
EClinicalMedicine. 2020 Jun 28;24:100432
pubmed: 32637902
Front Immunol. 2018 Sep 20;9:2134
pubmed: 30294326
N Engl J Med. 2020 Sep 17;383(12):1149-1155
pubmed: 32937047
Blood. 2022 Aug 11;140(6):594-607
pubmed: 35580269
Br J Haematol. 2021 Sep;194(5):e84-e89
pubmed: 34046889
Front Immunol. 2018 Nov 28;9:2722
pubmed: 30546360
Front Oncol. 2021 Feb 15;10:575168
pubmed: 33659205
Br J Haematol. 2021 Mar;192(5):869-878
pubmed: 33216361
Front Immunol. 2021 Apr 12;12:667515
pubmed: 33912194
Ann Hematol. 2021 May;100(5):1351-1353
pubmed: 32405694
Blood. 2010 Apr 1;115(13):2704-8
pubmed: 20089963
Haematologica. 2022 Apr 01;107(4):996-999
pubmed: 35021604
Case Rep Nephrol Dial. 2019 Nov 13;9(3):149-157
pubmed: 31828078
J Am Soc Nephrol. 2019 Jul;30(7):1206-1219
pubmed: 31227636